1. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol Suppl. 1995. 168:7–12.
2. Sugaya K, Kadekawa K, Ikehara A, Nakayama T, Gakiya M, Nashiro F, et al. Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia. Int J Urol. 2003. 10:569–575.
Article
3. Tanaka Y, Masumori N, Itoh N, Sato Y, Takahashi A, Ogura H, et al. Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia. J Urol. 2002. 167:2492–2495.
Article
4. Okada H, Kamidono S, Yoshioka T, Okuyama A, Ozono S, Hirao Y, et al. A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. BJU Int. 2000. 85:676–681.
Article
5. Lee E, Lee C. Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol. 1997. 80:606–611.
Article
6. Lepor H, Auerbach S, Puras-Baez A, Narayan P, Soloway M, Lowe F, et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol. 1992. 148:1467–1474.
Article
7. Kumamoto Y, Tsukamoto T, Yachiku S. Clinical evaluation of terazosin hydrochloride on urinary obstruction caused by benign prostatic hypertrophy (II): Double-blind comparative study compared with placebo. Hinyoukigeka. 1992. 5:823–840.
8. Nakamura S, Ishiyama S, Kobayashi Y, Tokue A. Clinical effect of terazosin hydrochloride on benign prostatic hypertrophy: examination by whole day uroflowmetry. Jpn J Urol Surg. 1992. 5:447–451.
9. Ebihara A, Kondo K, Ohashi K. Pharmacokinetics and pharmacological properties of terazosin hydrochloride, a new α1-blocker: a single dose study on Japanese healthy subjects. Clin Med Pharmaceut. 1987. 3:667–679.
10. Stone EA, Zhang Y, Rosengarten H, Yeretsian J, Quartermain D. Brain alpha 1-adrenergic neurotransmission is necessary for behavioral activation to environmental change in mice. Neuroscience. 1999. 94:1245–1252.
Article
11. Rouquier L, Claustre Y, Benavides J. Alpha 1-adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: a microdialysis study. Eur J Pharmacol. 1994. 261:59–64.
Article
12. Guthrie RM, Siegel RL. A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the Hypertension and BPH Intervention Trial (HABIT). Clin Ther. 1999. 21:1732–1748.
Article
13. Lowe FC, Olson PJ, Padley RJ. Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications. Urology. 1999. 54:81–85.
Article
14. Lowe F, Tuttle J, Marks S, Steidle C, Jacobs T, Padley RJ. The HYCAT investigator group. Blood pressure effects of men with prostatism concurrently treated with anti-hypertensives and terazosin. J Urol. 1995. 153:176. (272A).
15. Lowe FC. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. Urology. 1994. 44:46–51.
Article
16. Lenz ML, Pool JL, Laddu AR, Varghese A, Johnston W, Taylor AA. Combined terazosin and verapamil therapy in essential hypertension. Hemodynamic and pharmacokinetic interactions. Am J Hypertens. 1995. 8:133–145.
Article
17. Lepor H, Jones K, Williford W. The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study. J Urol. 2000. 163:1134–1137.
Article